PhotoCure ASA - Financial Events 2003

PhotoCure ASA has scheduled financial events as follows for 2003:

26.02.2003 - Financial Accounts 2002
03.04.2003 - General Meeting
13.05.2003 - Report 1st Quarter 2003
19.08.2003 - Report 2nd Quarter 2003
06.11.2003 - Report 3rd Quarter 2003

Oslo 15th of November 2002.

Note to the Editor:

PhotoCure ASA is a Norwegian listed company with the mission to develop and sell pharmaceuticals and medical devices in dermatology and oncology. The company develops products for skin cancer and other skin diseases, internal cancer, gene therapy and cancer vaccines. Metvix® PDT is developed for the treatment of basal cell carcinoma (skin cancer) and actinic keratosis (pre-cancerous skin lesions). Metvix® PDT is currently approved in 14 European countries and in New Zealand. PhotoCure is responsible for sales and marketing of Metvix® PDT in the Nordic countries, while global dermatology specialist, Galderma, is responsible for sales and marketing of Metvix® in the rest of the world. PhotoCure's second pharmaceutical product, Hexvix®, is currently undergoing clinical Phase III trials in the US and Europe for bladder cancer detection.

PCI Biotech AS, a subsidiary of PhotoCure ASA, is focused on the opportunities for photochemical internalisation (PCI) in drug discovery, development and delivery of novel cancer therapeutics.

The full quarterly report is available at our web site (www.photocure.com) at: /Investors/Reports/Quarterly reports.

For more information, contact:

PhotoCure ASA

Attn. Vidar Hansson, CEO

Hoffsveien 48

NO-0377 Oslo

Norway

www.photocure.com

E-mail: vh@photocure.no

Telephone: +47 22 06 22 10
Mobile: +47 90 73 78 72

Fax: +47 22 06 22 18